Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Javelin Pharmaceuticals has said that Dyloject has been accepted by the Scottish Medicines Consortium or SMC for use within the National Health Service Scotland, for the treatment or prevention of postoperative pain by intravenous injection.
Subscribe to our email newsletter
Dyloject will be available at the National Health Service tariff price of GBP48 per pack (10 x 75mg/2ml vials). The SMC has said that the manufacturer’s submission related only to intravenous use of diclofenac (Dyloject) in the post-operative setting. SMC cannot recommend its use by the intramuscular route.
Derek Gallacher, European managing director for Javelin, said: “This is a significant decision. Not only is Javelin now able to commercialize Dyloject in Scotland which represents approximately eight percent of the UK market, but the SMC assessment is viewed extremely favorably by other Health Technology assessment bodies throughout Europe.”